Literature DB >> 10993991

Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.

S D Silberstein1.   

Abstract

Entities:  

Mesh:

Year:  2000        PMID: 10993991     DOI: 10.1212/wnl.55.6.754

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  265 in total

Review 1.  Management of headache in the elderly.

Authors:  Matthew S Robbins; Richard B Lipton
Journal:  Drugs Aging       Date:  2010-05       Impact factor: 3.923

2.  Comparison of parenteral treatments of acute primary headache in a large academic emergency department cohort.

Authors:  Lucas H McCarthy; Robert P Cowan
Journal:  Cephalalgia       Date:  2014-11-03       Impact factor: 6.292

Review 3.  Migraine: diagnosis and management.

Authors:  Giles Elrington
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-06       Impact factor: 10.154

4.  Headache.

Authors:  Ian Bone; Geraint Fuller
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-06       Impact factor: 10.154

5.  Medicolegal issues in cluster headache.

Authors:  Elizabeth Loder; John Loder
Journal:  Curr Pain Headache Rep       Date:  2004-04

6.  Phenothiazines in migraine treatment.

Authors:  Marcelo E Bigal
Journal:  Curr Pain Headache Rep       Date:  2010-08

Review 7.  Controversies in migraine: monotherapy.

Authors:  Domenico D'Amico
Journal:  Neurol Sci       Date:  2012-05       Impact factor: 3.307

8.  Headache Disorders in the Elderly.

Authors:  Thomas N. Ward
Journal:  Curr Treat Options Neurol       Date:  2002-09       Impact factor: 3.598

9.  Acute Treatment of Migraine Headache.

Authors:  Marcelo E. Bigal; Richard B. Lipton
Journal:  Curr Treat Options Neurol       Date:  2003-11       Impact factor: 3.598

10.  Alternative Therapies for Headache.

Authors:  William B. Young; Patricia Pozo-Rosich; Mary F. Paolone
Journal:  Curr Treat Options Neurol       Date:  2003-11       Impact factor: 3.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.